Thromboxane inhibition with burimamide

Abstract

The disclosure describes a method for selectively inhibiting thromboxane biosynthesis with Burimamide, a compound previously known to be a histamine H 2 -receptor blocker. The discovery is useful in the treatment of a number of cardiovascular and inflammatory diseases in which thromboxane biosynthesis is involved.

We claim: 
     
       1. A method for treatment of an imflammatory disease condition comprising the administration to a human or animal suffering from an inflammatory disease condition of an effective, anti-inflammatory amount of Burimamide or a pharmaceutically acceptable salt thereof. 
     
     
       2. The method of claim 1 wherein the inflammatory disease is psoriasis. 
     
     
       3. The method of claim 1 wherein the inflammatory disease is allergy. 
     
     
       4. The method of claim 1 wherein the inflammatory disease is eczema. 
     
     
       5. The method of claim 1 wherein the inflammatory disease is pruritis. 
     
     
       6. The method of claim 1 wherein the inflammatory disease is inflammation of the eye. 
     
     
       7. The method of claim 1 wherein the inflammatory disease is asthma.